Abstract
Aim. To complete DNA-diagnostics for the patients with syncopes and not showing clinically significant rhythm disorders, but with family anamnesis of sudden death. Material and methods. Clinical case. The patient 22 y.o. consulted at RSCS n.a.Petrovsky with the primary diagnosis of "inherited epilepsy" and complaints on presyncopes and dizziness. During examination there was no data found to prove the inherited epilepsy and clinically significant rhythm disorders. Taking into account the family anamnesis of sudden death a dignosis of "idiopathic ventricular tachycardia" was suggested and the patient underwent two-chamber rate-adaptive cardioverter-defibrillator Maximo II DR D284DRG implantation. DNA-testing revealed a mutation of p.R583H in the gene KCNQ1, that had been previously described as probable to cause type 1 long-QT-syndrome. During the next 12 month after implantation there were 2 proven strobes recorded. The patient was consulted by cardiologist to prescribe beta-blocker therapy. Results. Although there were no clinically significant heart rhythm disorders found, the patient with suspected family type of idiopathic ventricular tachicardia underwent cardioverter-defibrillator setting up procedure. Molecular-genetic methods helped to prove the diagnosis of "long-QT-syndrome type 1" and the cascade family screening was started to choose a treatment strategy for asymptopathic mutation bearers. Conclusion. By the example of the clinical case described we showed a significance of DNA-diagnostics in the diagnosis clarification, treatment strategy choice and sufficient medical-genetic consulting for the disease mentioned.
Highlights
There were no clinically significant heart rhythm disorders found, the patient with suspected family type of idiopathic ventricular tachicardia underwent cardioverter-defibrillator setting up procedure
By the example of the clinical case described we showed a significance of DNA-diagnostics in the diagnosis clarification, treatment strategy choice and sufficient medical-genetic consulting for the disease mentioned
Согласно рекомендациям Европейского общества кардиологов (HRS/EHRA/APHRS CONSENSUS STATEMENT, 2013), бета-блокаторы могут быть эффективны в снижении риска внезапной сердечной смерти (ВСС) у больных с нормальной продолжительностью интервала QTc и только с молекулярно-генетическим диагнозом LQTS (класс рекомендаций IIa) [4]
Summary
В. Петровского РАМН, Москва; 2Научный центр сердечно-сосудистой хирургии им. М.н., отделение хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции, Глазова О. М.н., главный научный сотрудник отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции, Заклязьминская Е.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.